rAAV-CD39

rAAV-CD39 is a recombinant adeno-associated virus (rAAV) vector-based gene therapy designed to express CD39 (ectonucleoside triphosphate diphosphohydrolase 1). CD39 is a membrane-bound apyrase that catalyzes the degradation of extracellular adenosine triphosphate (eATP) and adenosine diphosphate (ADP) into adenosine monophosphate (AMP). In asthma, elevated levels of eATP in the bronchoalveolar lavage fluid act as a danger signal, promoting eosinophilia, Th2 cytokine production, and airway hyperresponsiveness (AHR). By overexpressing CD39 in the lungs, rAAV-CD39 aims to lower eATP levels and alleviate asthmatic airway inflammation. This approach has been investigated in preclinical models by researchers at China Medical University, demonstrating its potential as a gene therapy for asthma.